428 related articles for article (PubMed ID: 32799491)
1. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
2. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
[TBL] [Abstract][Full Text] [Related]
3. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
Yao H; Gunawan YF; Liu G; Tse MK; Zhu G
Dalton Trans; 2021 Oct; 50(39):13737-13747. PubMed ID: 34519297
[TBL] [Abstract][Full Text] [Related]
4. Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
Spector D; Bubley A; Zharova A; Bykusov V; Skvortsov D; Ipatova D; Erofeev A; Gorelkin P; Vaneev A; Mazur D; Nikitina V; Melnikov M; Pergushov V; Bunin D; Kuzmin V; Kostyukov A; Egorov A; Beloglazkina E; Akasov R; Krasnovskaya O
ACS Appl Bio Mater; 2024 May; 7(5):3431-3440. PubMed ID: 38697834
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells.
Yao H; Xu Z; Li C; Tse MK; Tong Z; Zhu G
Inorg Chem; 2019 Aug; 58(16):11076-11084. PubMed ID: 31393117
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
Harringer S; Hejl M; Enyedy ÉA; Jakupec MA; Galanski MS; Keppler BK; Dyson PJ; Varbanov HP
Dalton Trans; 2021 Jun; 50(23):8167-8178. PubMed ID: 34031671
[TBL] [Abstract][Full Text] [Related]
7. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Circulation and Tumor Accumulation of Carboplatin via an Erythrocyte-Anchored Prodrug Strategy.
Yao H; Wang Z; Wang N; Deng Z; Liu G; Zhou J; Chen S; Shi J; Zhu G
Angew Chem Int Ed Engl; 2022 Jun; 61(25):e202203838. PubMed ID: 35352863
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
Min Y; Li J; Liu F; Yeow EK; Xing B
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
[TBL] [Abstract][Full Text] [Related]
10. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
11. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug.
Krasnovskaya OO; Akasov RA; Spector DV; Pavlov KG; Bubley AA; Kuzmin VA; Kostyukov AA; Khaydukov EV; Lopatukhina EV; Semkina AS; Vlasova KY; Sypalov SA; Erofeev AS; Gorelkin PV; Vaneev AN; Nikitina VN; Skvortsov DA; Ipatova DA; Mazur DM; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12882-12894. PubMed ID: 36854172
[TBL] [Abstract][Full Text] [Related]
12. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
13. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin prodrug conjugated Fe
Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
[TBL] [Abstract][Full Text] [Related]
15. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
16. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
17. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
18. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
[TBL] [Abstract][Full Text] [Related]
19. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
[TBL] [Abstract][Full Text] [Related]
20. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
